172 related articles for article (PubMed ID: 37759751)
21. Structural insights into the function of steroidogenic cytochrome P450 17A1.
Yadav R; Petrunak EM; Estrada DF; Scott EE
Mol Cell Endocrinol; 2017 Feb; 441():68-75. PubMed ID: 27566228
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and biochemical evaluation of a range of potent benzyl imidazole-based compounds as potential inhibitors of the enzyme complex 17alpha-hydroxylase/17,20-lyase (P450(17alpha)).
Owen CP; Dhanani S; Patel CH; Shahid I; Ahmed S
Bioorg Med Chem Lett; 2006 Aug; 16(15):4011-5. PubMed ID: 16750362
[TBL] [Abstract][Full Text] [Related]
23. Hydroxylation and lyase reactions of steroids catalyzed by mouse cytochrome P450 17A1 (Cyp17a1).
Lee SG; Kim V; Lee GH; Kim C; Jeong E; Guengerich FP; Kim D
J Inorg Biochem; 2023 Mar; 240():112085. PubMed ID: 36640554
[TBL] [Abstract][Full Text] [Related]
24. 1-Heteroaryl-3-phenoxypropan-2-ones as inhibitors of cytosolic phospholipase A₂α and fatty acid amide hydrolase: Effect of the replacement of the ether oxygen with sulfur and nitrogen moieties on enzyme inhibition and metabolic stability.
Sundermann T; Fabian J; Hanekamp W; Lehr M
Bioorg Med Chem; 2015 May; 23(10):2579-92. PubMed ID: 25862211
[TBL] [Abstract][Full Text] [Related]
25. SPR-Based study of affinity of cytochrome P450s / redox partners interactions modulated by steroidal substrates.
Ershov PV; Yablokov ЕO; Florinskaya AV; Mezentsev YV; Kaluzhskiy LА; Tumilovich AM; Gilep АА; Usanov SA; Ivanov АS
J Steroid Biochem Mol Biol; 2019 Mar; 187():124-129. PubMed ID: 30468857
[TBL] [Abstract][Full Text] [Related]
26. New aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the hydroxytriazole scaffold.
Pippione AC; Kilic-Kurt Z; Kovachka S; Sainas S; Rolando B; Denasio E; Pors K; Adinolfi S; Zonari D; Bagnati R; Lolli ML; Spyrakis F; Oliaro-Bosso S; Boschi D
Eur J Med Chem; 2022 Jul; 237():114366. PubMed ID: 35447434
[TBL] [Abstract][Full Text] [Related]
27. Limited expression of cytochrome p450 17α-hydroxylase/17,20-lyase in prostate cancer cell lines.
Jeong CW; Yoon CY; Jeong SJ; Hong SK; Byun SS; Lee SE
Korean J Urol; 2011 Jul; 52(7):494-7. PubMed ID: 21860772
[TBL] [Abstract][Full Text] [Related]
28. Modified bile acids and androstanes-Novel promising inhibitors of human cytochrome P450 17A1.
Dzichenka Y; Shapira M; Yantsevich A; Cherkesova T; Grbović L; Savić M; Usanov S; Jovanović-Šanta S
J Steroid Biochem Mol Biol; 2021 Jan; 205():105777. PubMed ID: 33157220
[TBL] [Abstract][Full Text] [Related]
29. Human cytochrome P450 17A1 conformational selection: modulation by ligand and cytochrome b5.
Estrada DF; Skinner AL; Laurence JS; Scott EE
J Biol Chem; 2014 May; 289(20):14310-20. PubMed ID: 24671419
[TBL] [Abstract][Full Text] [Related]
30. The diverse chemistry of cytochrome P450 17A1 (P450c17, CYP17A1).
Yoshimoto FK; Auchus RJ
J Steroid Biochem Mol Biol; 2015 Jul; 151():52-65. PubMed ID: 25482340
[TBL] [Abstract][Full Text] [Related]
31. Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.
Penning TM
Expert Opin Ther Pat; 2017 Dec; 27(12):1329-1340. PubMed ID: 28895472
[TBL] [Abstract][Full Text] [Related]
32. Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors.
Penning TM; Steckelbroeck S; Bauman DR; Miller MW; Jin Y; Peehl DM; Fung KM; Lin HK
Mol Cell Endocrinol; 2006 Mar; 248(1-2):182-91. PubMed ID: 16417966
[TBL] [Abstract][Full Text] [Related]
33. Synthesis, 17α-hydroxylase-C
Banday AH; Shameem SA; Banday JA; Ganaie BA
Anticancer Agents Med Chem; 2018; 18(13):1919-1926. PubMed ID: 29697032
[TBL] [Abstract][Full Text] [Related]
34. Structures of human steroidogenic cytochrome P450 17A1 with substrates.
Petrunak EM; DeVore NM; Porubsky PR; Scott EE
J Biol Chem; 2014 Nov; 289(47):32952-64. PubMed ID: 25301938
[TBL] [Abstract][Full Text] [Related]
35. Crystal structures of three classes of non-steroidal anti-inflammatory drugs in complex with aldo-keto reductase 1C3.
Flanagan JU; Yosaatmadja Y; Teague RM; Chai MZ; Turnbull AP; Squire CJ
PLoS One; 2012; 7(8):e43965. PubMed ID: 22937138
[TBL] [Abstract][Full Text] [Related]
36. X-ray structure of human aldo-keto reductase 1C3 in complex with a bile acid fused tetrazole inhibitor: experimental validation, molecular docking and structural analysis.
Marinović MA; Bekić SS; Kugler M; Brynda J; Škerlová J; Škorić DĐ; Řezáčová P; Petri ET; Ćelić AS
RSC Med Chem; 2023 Feb; 14(2):341-355. PubMed ID: 36846371
[TBL] [Abstract][Full Text] [Related]
37. Prospective computational design and in vitro bio-analytical tests of new chemical entities as potential selective CYP17A1 lyase inhibitors.
Gumede NJ; Nxumalo W; Bisetty K; Escuder Gilabert L; Medina-Hernandez MJ; Sagrado S
Bioorg Chem; 2020 Jan; 94():103462. PubMed ID: 31818479
[TBL] [Abstract][Full Text] [Related]
38. Mechanism of the Dual Activities of Human CYP17A1 and Binding to Anti-Prostate Cancer Drug Abiraterone Revealed by a Novel V366M Mutation Causing 17,20 Lyase Deficiency.
Fernández-Cancio M; Camats N; Flück CE; Zalewski A; Dick B; Frey BM; Monné R; Torán N; Audí L; Pandey AV
Pharmaceuticals (Basel); 2018 Apr; 11(2):. PubMed ID: 29710837
[TBL] [Abstract][Full Text] [Related]
39. A missense mutation in the human cytochrome b5 gene causes 46,XY disorder of sex development due to true isolated 17,20 lyase deficiency.
Idkowiak J; Randell T; Dhir V; Patel P; Shackleton CH; Taylor NF; Krone N; Arlt W
J Clin Endocrinol Metab; 2012 Mar; 97(3):E465-75. PubMed ID: 22170710
[TBL] [Abstract][Full Text] [Related]
40. Cytochrome b5: novel roles in steroidogenesis.
Storbeck KH; Swart AC; Goosen P; Swart P
Mol Cell Endocrinol; 2013 May; 371(1-2):87-99. PubMed ID: 23228600
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
